NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
Taking everything into account, AMGN scores 5 out of 10 in our fundamental rating. AMGN was compared to 561 industry peers in the Biotechnology industry. AMGN has an excellent profitability rating, but there are some minor concerns on its financial health. AMGN is not valued too expensively and it also shows a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.64% | ||
ROE | 95.59% | ||
ROIC | 11.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 25.22% | ||
PM (TTM) | 17.39% | ||
GM | 64.07% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.7 | ||
Debt/FCF | 5.26 | ||
Altman-Z | 1.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.17 | ||
Quick Ratio | 0.88 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.1 | ||
Fwd PE | 12.41 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 13.39 | ||
EV/EBITDA | 13.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.5% |
271.9
+0.56 (+0.21%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.5% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.1 | ||
Fwd PE | 12.41 | ||
P/S | 4.28 | ||
P/FCF | 13.39 | ||
P/OCF | 11.99 | ||
P/B | 23.55 | ||
P/tB | N/A | ||
EV/EBITDA | 13.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.64% | ||
ROE | 95.59% | ||
ROCE | 12.97% | ||
ROIC | 11.3% | ||
ROICexc | 13.03% | ||
ROICexgc | 56.9% | ||
OM | 25.22% | ||
PM (TTM) | 17.39% | ||
GM | 64.07% | ||
FCFM | 31.98% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.7 | ||
Debt/FCF | 5.26 | ||
Debt/EBITDA | 3.81 | ||
Cap/Depr | 22.89% | ||
Cap/Sales | 3.74% | ||
Interest Coverage | 250 | ||
Cash Conversion | 85.93% | ||
Profit Quality | 183.97% | ||
Current Ratio | 1.17 | ||
Quick Ratio | 0.88 | ||
Altman-Z | 1.38 |